HSBC Initiates Coverage On Biogen with Buy Rating, Announces Price Target of $360
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Morten Herholdt has initiated coverage on Biogen (NASDAQ:BIIB) with a Buy rating and a price target of $360.
September 06, 2023 | 9:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HSBC has initiated coverage on Biogen with a Buy rating and a price target of $360, indicating positive sentiment towards the stock.
The initiation of coverage by HSBC with a Buy rating and a high price target indicates a positive outlook for Biogen. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100